Article Text

Supporting adherence for people starting a new medication for a long-term condition through community pharmacies: a pragmatic randomised controlled trial of the New Medicine Service
  1. Rachel Ann Elliott1,2,
  2. Matthew J Boyd2,
  3. Nde-Eshimuni Salema2,
  4. James Davies3,
  5. Nicholas Barber4,
  6. Rajnikant Laxmishanker Mehta5,
  7. Lukasz Tanajewski2,6,
  8. Justin Waring7,
  9. Asam Latif2,
  10. Georgios Gkountouras2,6,
  11. A J Avery8,
  12. Antony Chuter1,
  13. Christopher Craig2
  1. 1School of Pharmacy, University of Nottingham, Nottingham, UK
  2. 2Division of Social Research in Medicines and Health, University of Nottingham School of Pharmacy, Nottingham, UK
  3. 3Department of Policy and Research, The Company Chemists’ Association, London, UK
  4. 4Health Foundation, London, UK
  5. 5School of Medicine, University of Nottingham, Nottingham, UK
  6. 6School of Pharmacy, University of Nottingham, Nottingham, UK
  7. 7Nottingham University Business School, University of Nottingham, Nottingham, UK
  8. 8Division of Primary Care, School of Community Health Sciences, Primary Care, University of Nottingham, Nottingham, UK
  1. Correspondence to Professor Rachel Ann Elliott, School of Pharmacy, University of Nottingham, University Park, Nottingham NG7 2RD, UK; rachel.elliott{at}


Objective To examine the effectiveness of the New Medicine Service (NMS), a national community pharmacy service to support medicines-taking in people starting a new medicine for a long-term condition, compared with normal practice.

Methods Pragmatic patient-level parallel randomised controlled trial, in 46 community pharmacies in England. Patients 1:1 block randomisation stratified by drug/disease group within each pharmacy. 504 participants (NMS: 251) aged 14 years and over, identified in the pharmacy on presentation of a prescription for asthma/chronic obstructive pulmonary disease, hypertension, type 2 diabetes or an anticoagulant/antiplatelet agent. NMS intervention: One consultation 7–14 days after presentation of prescription followed by another 14–21 days thereafter to identify problems with treatment and provide support if needed. Controls received normal practice. Adherence, defined as missing no doses without the advice of a medical professional in the previous 7 days, was assessed through patient self-report at 10 weeks. Intention-to-treat analysis was employed, with outcome adjusted for recruiting pharmacy, NMS disease category, age, sex and medication count. Cost to the National Health Service (NHS) was collected.

Results At 10 weeks, 53 patients had withdrawn and 443 (85%) patients were contacted successfully by telephone. In the unadjusted analysis of 378 patients still taking the initial medicine, 61% (95% CI 54% to 67%) and 71% (95% CI 64% to 77%) patients were adherent in the normal practice and NMS arms, respectively (p=0.04 for difference). In the adjusted intention-to-treat analysis, the OR for increased adherence was 1.67 (95% CI 1.06 to 2.62; p=0.027) in favour of the NMS arm. There was a general trend to reduced NHS costs, albeit, statistically non-significant, for the NMS intervention: saving £21 (95% CI −£59 to £100, p=0.128) per patient.

Conclusions The NMS significantly increased the proportion of patients adhering to their new medicine by about 10%, compared with normal practice.

Trial registration numbers trial reference number NCT01635361 ( Current Controlled trials: trial reference number ISRCTN 23560818 (; DOI 10.1186/ISRCTN23560818). UK Clinical Research Network (UKCRN) study 12494 (

  • Chronic disease management
  • Compliance
  • Patient-centred care
  • Pharmacists
  • Randomised controlled trial

This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See:

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Supplementary materials

  • Supplementary Data

    This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

Linked Articles